Pharnext to Attend November Investors Conferences
Pharnext SA (FR0011191287 - ALPHA)(Paris:ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that senior management will be attending the following conferences taking place in November 2017 throughout Europe.
- BIO-Europe® 2017 1 , on November 6-8, 2017 at CityCube Berlin, Berlin, Germany.
- Jefferies 2017 London Healthcare Conference 2 on November 16, 2017 in London, United Kingdom.
on November 23-24, 2017 at Palais
des Congrès, Paris, France.
- Corporate Overview Presentation : during "Facing the leaders" on November 23, from 3:45pm to 4:00pm CET. Speaker : Mr. Olivier Legrand, Pharnext.
- Geneva European Midcap Event 4 on November 28, 2017 in Geneva, Switzerland.
If you are interested in meeting the Pharnext management team during either of these events or if you need more information about Pharnext's participation, please send an email to email@example.com .
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit www.pharnext.com .
Xavier Paoli, +33 (0)1-4109-2230
VP, Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1-212-362-1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1-5688-1115
Media Relations (Europe)
Media Relations (U.S.)
Marion Janic, +1-212-223-4017
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ABB23.4.2018 16:37 | pressemeddelelse
ABB and the Economist Launch Automation Readiness Index, Global Ranking for Robotics and Artificial Intelligence
FINABLR23.4.2018 14:57 | pressemeddelelse
Finablr Launched To Accelerate Customer-Focused Technology Innovations
ABU-DHABI-FUND-DEVELOPME23.4.2018 14:39 | pressemeddelelse
Abu Dhabi Fund for Development Finances US$192 Million Sheikh Khalifa bin Zayed City in Afghanistan
SIARA23.4.2018 14:02 | pressemeddelelse
Malaysian Foundation Recognised for Refugee Support by Sharjah with USD 136,000
WI-ROCKWELL-AUTOMATION23.4.2018 14:02 | pressemeddelelse
Rockwell Automation Simplifies Analytics for Industrial Productivity
PSMF23.4.2018 14:02 | pressemeddelelse
Sixteen Healthcare Groups Make Major Commitments at 2nd Annual Patient Safety Rally in Taiwan
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum